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Background: Plasmodium falciparum circumsporozoite protein (CSP) is a leading malaria vaccine candidate antigen,
known to elicit protective antibody responses in humans (RTS,S vaccine). Recently, a DNA prime / adenovirus (Ad)
vector boost vaccine encoding CSP and a second P. falciparum antigen, apical membrane antigen-1, also elicited
sterile protection, but in this case associated with interferon gamma ELISpot and CD8+ T cell but not antibody
responses. The finding that CSP delivered by an appropriate vaccine platform likely elicits protective cell-mediated
immunity provided a rationale for identifying class I-restricted epitopes within this leading vaccine candidate
antigen.
Methods: Limited samples of peripheral blood mononuclear cells from clinical trials of the Ad vaccine were used
to identify CD8+ T cell epitopes within pools of overlapping 15mer peptides spanning portions of CSP that
stimulated recall responses. Computerized algorithms (NetMHC) predicted 17 minimal class I-restricted 9-10mer
epitopes within fifteen 15mers positive in ELISpot assay using PBMC from 10 HLA-matched study subjects. Four
additional epitopes were subsequently predicted using NetMHC, matched to other study subjects without initial
15mer ELISpot screening. Nine of the putative epitopes were synthesized and tested by ELISpot assay, and six of
these nine were further tested for CD8+ T cell responses by ELISpot CD4+ and CD8+ T cell-depletion and flow
cytometry assays for evidence of CD8+ T cell dependence.
Results: Each of the nine putative epitopes, all sequence-conserved, recalled responses from HLA-matched
CSP-immunized research subjects. Four shorter sequences contained within these sequences were identified using
NetMHC predictions and may have contributed to recall responses. Five (9-10mer) epitopes were confirmed to be
targets of CD8+ T cell responses using ELISpot depletion and ICS assays. Two 9mers among these nine epitopes were
each restricted by two HLA supertypes (A01/B07; A01A24/A24) and one 9mer was restricted by three HLA supertypes
(A01A24/A24/B27) indicating that some CSP class I-restricted epitopes, like DR epitopes, may be HLA-promiscuous.
Conclusions: This study identified nine and confirmed five novel class I epitopes restricted by six HLA supertypes,
suggesting that an adenovirus-vectored CSP vaccine would be immunogenic and potentially protective in genetically
diverse populations.
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The circumsporozoite protein (CSP) is the main antigenic
component of several candidate malaria vaccines, inclu-
ding the RTS,S vaccine currently undergoing Phase 3
testing in sub-Saharan Africa. RTS,S induces anti-CSP
antibodies thought to mediate protection by targeting
sporozoites, inhibiting motility and hepatocyte invasion
[1]. This proposed mechanism is supported by the finding
that both antibody and CD4+ T cell responses to CSP cor-
relate with protection [1]. CD8+ T cell responses, however,
have not been consistently demonstrated in individuals
vaccinated with RTS,S [1,2]. Thus it is not clear whether
RTS,S additionally targets the liver stages of Plasmodium,
where immunity appears to be CD8+ T cell dependent [3].
CSP is carried into hepatocytes by invading sporozoites
[4] and is expressed as peptides on the surface of the
infected hepatocytes in the context of MHC Class I,
potentially allowing recognition by CSP-specific CD8+ T
cells [5]. Vaccine platforms such as adenovirus vectors
promoting the induction of CD8+ T cell responses to CSP
or other antigens expressed on the surface of infected he-
patocytes might therefore improve protection against liver
stage parasites [6].
To this aim, a replication-deficient adenovirus (Ad)-
vectored vaccine encoding Plasmodium falciparum CSP
(PfCSP) (NMRC-MV-Ad-PfC, or Ad-C) was tested in
humans. The vaccine, based on human adenovirus sero-
type 5, was tested by itself and in combination with a
second Ad vector encoding apical membrane antigen-1
(AMA1) (NMRC-MV-Ad-PfA, or Ad-A). Both Ad-C
and Ad-CA (the combination of Ad-C and Ad-A) vac-
cines elicited robust CD8+ T cell responses against both
antigens [7-9], similar to other Ad-based vaccines under
development for different pathogens [10]. AMA1 was
added to CSP because AMA1 is likewise involved in
hepatocyte invasion by the malaria parasite [11], and
AMA1 peptides may similarly be expressed on the
surface of infected hepatocytes. Simultaneous expression
of peptides derived from both antigens could facilitate
targeting by effector CD8+ T cells. To further enhance
cell-mediated responses, the combination Ad-CA vac-
cine was primed with three doses of DNA expressing
CSP and AMA1. The resulting DNA/Ad regimen in-
duced sterile protection against controlled human mal-
aria infection (CHMI) in 27% of immunized volunteers,
with protection significantly correlated with CD8+ T cell
interferon-gamma responses [12]. Antibody responses
were relatively low, and did not correlate with protec-
tion, consistent with the hypothesis that CD8+ T cells
may be the primary immune effector targeting liver stage
parasites in humans [3].
The aim of the current study was to identify the class I
CD8+ T cell epitopes in CSP recognized by the cell-
mediated responses to the Ad-C and Ad-CA vaccines.Such epitopes could be used in the design of epitope-
based vaccines, and responses to these epitopes could be
assessed prospectively as potential correlates of protection
induced by the DNA/Ad vaccine or other CSP-based
vaccines. Previously, 14 class I-restricted epitopes were
identified within AMA1, using a combination of predictive
algorithms (NetMHC [13]) and cellular immunoassays
[14]. The current study applied similar methods to map
class I-restricted epitopes in CSP.
PfCSP (3D7 strain) contains 397 amino acids (aa), with
the N-terminal region spanning aa 1–104, the central
repeat region spanning aa 105–272, and the C-terminal
region spanning aa 273–397 (Figure 1). The C-terminal
region contains the thrombospondin-like type 1 repeat
domain [15] overlapping the Th2R and Th3R T epitope
regions [16]. While the RTS,S vaccine contains aa 207–
395 [17], and therefore lacks the N-terminal region [18],
the Ad-C vaccine is full length except for a deletion of
16 repeats (64 aa) between 209–272 (leaving 26 repeats
intact), and the insertion of a 23 aa tail at the C-
terminus, derived from the 3’-noncoding bovine growth
hormone polyadenylation sequence [7,8].
A summary of previously published DR-restricted
epitopes identified in CSP is shown in Figure 1. These
DR-restricted epitopes were identified using malaria-
endemic volunteers or volunteers immunized with
radiation-attenuated sporozoites (RAS). Three DR-
restricted epitopes, D43, D44 and D50 [19-21], were ori-
ginally characterized using class II binding assays to
identify peptides that recalled proliferative responses
from individuals living in a malaria-endemic area; D10,
D45, D49, Th2R and Th3R [22] were characterized using
overlapping peptides to recall proliferative responses, like-
wise from individuals living in malaria-endemic areas; and
CS.T3 was identified using proliferation assays testing
samples from volunteers immunized with RAS [23].
Previously published class I-restricted CSP epitopes
are also shown in Figure 1, and have been identified in
both the N- and C-terminal regions. D1, D2, D3, and D6
were identified using class I binding assays to identify
peptides that induced cytotoxic recall activities from vol-
unteers immunized with RAS and from malaria-endemic
volunteers [24,25]; D4 was identified using peptides to
recall proliferation responses from malaria-endemic
volunteers [26]; and D5, D7, D8 and D9 were character-
ized using short peptides designed to match the HLA of
malaria-endemic volunteers [27,28]. D5 and D9 have
been tested in mice for induction of cytotoxic T cell re-
sponses [29]. More recently, D4, D5 and D6 were shown
to recall interferon-gamma responses in ELISpot assays
using PBMCs from individuals living in a malaria-
endemic region of Ghana [30].
HLA alleles have been grouped into nine supertypes
that are clusters of alleles with similar peptide-binding
Figure 1 Plasmodium falciparum CSP: structure, vaccines and distribution of class I and class II-restricted epitopes. The structure of
P. falciparum CSP (3D7) comprises of N- and C-terminal regions flanking a central repeat region (Panel A). The N-terminal region contains a
conserved region R1, and the C-terminal region contains variable T epitope regions Th2R and Th3R that are contained within the
thrombospondin-like type I repeat (TSR), and ends in a region attached to the GPI anchor. The RTS,S vaccine contains part of the repeats and the
C-terminal region; the Ad-C vaccine contains full length CSP, except for a deletion of 16 NANP repeats (64 aa) leaving 26 repeats intact and for
an insertion of a 23 aa tail at the C terminus (derived from the 3’-noncoding bovine growth hormone polyadenylation sequence). Published class
II (Panel B) and class I (Panel C) epitopes occur in the N- and C-terminals. The sequences for the CSP peptide pools Cp1-Cp9 and the individual 15mers
within each of four dominant pools are listed (Panel D). Amino acids 1–39, 29–71, 309–331 and 357–397, corresponding to the four immunodominant
pools, were included in the analysis. Amino acids 72–308 and 332–356 were excluded. Panel E shows the new predicted class I-restricted epitopes
derived from the Cp1, Cp2, Cp6 and Cp9 15mers. Those that were confirmed in ELISpot depletion or ICS assays are boxed (Panel E).
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supertypes [31-33]. Based on algorithms that predict
binding to MHC molecules, measured as 50% inhibitory
concentration (IC50) values expressed as nanomolar
(nM) [34], a meta-analysis using an affinity cut-off of
500 nM predicted that 52% of a panel P. falciparum
peptides bound to HLA A*02:01 [35], and led to the
development of publically available algorithms that are
specific for class I and class II types [35]. The outcomes
of these and similar studies led to the establishment of
the Immune Epitope Database and Analysis Resource
(IEDB) that contains open access data and analytical
tools for malaria and a wide range of other organisms
[36]. Class II-restricted epitopes are well known to bepromiscuous, binding to multiple HLA alleles [37], includ-
ing DR-restricted epitopes in CSP [21]. Similar promiscuity
in class I-restricted epitopes has been described for malaria
antigens including CSP [24] and has been extended to in-
clude epitopes from other organisms [38,39]. Recently,
analysis of the IEDB data base suggests that >50% of HLA
class I-restricted ligands bind to two or more HLA mole-
cules often spanning different supertypes [40].
To conduct the mapping studies of CSP epitopes, per-
ipheral blood mononuclear cells (PBMC) were selected
from limited supplies of frozen specimens previously
collected from volunteers immunized with Ad-C or Ad-
CA in three different trials [7-9]. Nine CSP peptide pools
containing three to 12 overlapping 15mer peptides had
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trials to characterize responses in ELISpot assays and flow
cytometry, with four pools giving the highest responses
[7]. Since the numbers of frozen PBMC from these three
trials were limited, only these four CSP peptide pools
were used for epitope mapping, and for the same reason
(limited PBMC supplies), previously described class I
epitopes were not tested.
Methods
Vaccines and trial design
The vaccine used in this study was either the CSP-
encoding Ad vector alone (Ad-C) or the same in combin-
ation with AMA1-encoding Ad vector (Ad-CA), in three
different clinical trials (Figure 2). In the first trial, six vol-
unteers were immunized with 2 × 1010 particle units (pu)
of both adenovectors (Ad-CA) as a single intramuscular
dose, but there was no controlled human malaria infection
(CHMI) to determine efficacy in this small safety study
[7]. In the second trial, 18 volunteers were similarly im-
munized once with 2 × 1010 pu of Ad-CA, and in this trial
they underwent CHMI by bite of P. falciparum-infected
mosquitoes [9]. In the third trial, volunteers were immu-
nized twice with 1 × 1010 pu of Ad-C alone at week 0 (15
volunteers) and week 16 (14 volunteers). These research
subjects also underwent CHMI by bite of P. falciparum-
infected mosquitoes [8]. While none of the volunteers in
the two challenge studies was sterilely protected against
malaria (contrasting with the trial where DNA was first
used to prime the response), the Ad-alone vaccine-1 0 1 2 3 4 5 6 7 8 9 10
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Figure 2 Vaccine trials with adenovirus vectored CSP used to map CS
performed: trial 1 used Ad-C combined with adenovirus-vectored AMA (Ad
trial 2 used the same dose of Ad-CA given to 18 subjects followed by CHM
(to 15 and 14 subjects respectively) followed by CHMI four weeks later. Col
subjects that were used in this study are identified by trial. Challenge=CHMregimens were strongly immunogenic for CD8+ and
CD4+ T cell responses.
Volunteers and HLA typing
HLA molecular typing for HLA-A and HLA-B loci was
performed by the Department of Defense Bone Marrow
Donor Program using specific oligonucleotide probes to
amplify HLA Class I genes. Typing included a list of
allelic codes from which it was possible to assign each
volunteer to an HLA-A or HLA-B allele group using
code lists as previously described [14]. Each HLA-A or
HLA-B allele group was then assigned to HLA A or
HLA B supertypes according to published nomencla-
tures. All 17 volunteers from the three trials used in this
study, and their HLA A and B allele groups, are shown
in Table 1.
Peripheral blood mononuclear cells (PBMC)
The PBMC used in this study for epitope mapping were
collected 19–28 days following Ad administration, a
period corresponding to the peak response. In a few
cases where samples were insufficient, collections from
28 days post challenge (56 days post Ad administration)
were used instead, as responses to this vaccine in a prior
study persisted for at least 12 months in most research
subjects [7]. In summary, the PBMC samples were
obtained from the following time points: trial 1 (Ad-CA,
no CHMI), 28 days following immunization; trial 2 (Ad-
CA, with CHMI), 22–23 days after immunization and
28 days after challenge; trial 3 (Ad-C administered twice11 12 13 14 15 16 17 18 19 20 21 22
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P epitopes. Three trials using adenovirus-vectored CSP (Ad-C) were
-A) given as one immunization (Ad-CA) to six subjects without CHMI;
I four weeks later; trial 3 used Ad-C administered twice 16 weeks apart
lection points for PBMC used in this study are shown in boxes. The 17
I.
Table 1 Volunteer HLA A and B allele groups and supertypes
Vaccine Vol.
Strategy
Trial HLA-A1allele group
HLA-A2
allele group
HLA-B1
allele group
HLA-B2
allele group
HLA-A1
supertype
HLA-A2
supertype
HLA-B1
supertype
HLA-B2
supertype1A 1B 2
Ad-CA v1 x 1 A*02:01 A*26:01 B*18:01 B*44:02 A02 A01 B44 B44
v2 x 1 A*01:01 A*02:01 B*08:01 B*44:02 A01 A02 B08 B44
v5 x 1 A*01:01 A*68:02 B*08:01 B*14:02 A01 A02 B08 B27
v8 x 1 A*68:01 A*68:02 B*14:02 B*48:01 A03 A02 B27 B27
v12 x 1 A*30:02 A*68:01 B*18:01 B*58:02 A01 A03 B44 B58
Ad-CA v125 x 2 A*02:01 A*11:01 B*35:01 B*52:01 A02 A03 B07 B62
v127 x 2 A*01:01 A*24:02 B*08:01 B*44:05 A01 A24 B08 B44
v156 x x 2 A*03:01 A*29:02 B*15:03 B*58:02 A03 A01 A24 B27 B58
Ad-C v37 x x 3 A*23:01 A*68:02 B*15:03 B*53:01 A24 A02 B27 B07
v40 x x 3 A*23:01 A*29:02 B*52:01 B*53:01 A24 A01 B62 B07
v41 x 3 A*02:01 A*31:01 B*07:02 B*35:01 A02 A03 B07 B07
v49 x 3 A*33:01 A*74:01 B*15:03 B*15:03 A03 A03 B27 B27
v58 x x 3 A*02:01 A*24:02 B*08:01 B*38:02 A02 A24 B08 B271
v61 x 3 A*02:01 A*02:01 B*38:01 B*44:02 A02 A02 B27 B44
v63 x 3 A*11:01 A*24:03 B*40:01 B*51:04 A03 A24 B44 B07
v68 x 3 A*24:02 A*30:01 B*13:02 B*14:02 A24 A01 A03 B621 B27
v69 x x 3 A*30:02 A*34:02 B*14:02 B*35:01 A01 A03 B27 B07
The volunteers from whom PBMC were available and were tested are shown. Trial 1 (no CHMI): five of six volunteers immunized with Ad-CA were used (reference
7). Trial 2 (with CHMI): three of 17 volunteers immunized with Ad-CA and challenged by bite of P. falciparum-infected mosquitoes were used (Tamminga, in press).
Trial 3 (with CHMI): nine of 11 volunteers immunized with Ad-C and challenged by bite of P. falciparum-infected mosquitoes were used (reference 8). The table
also identifies the ten volunteers with best available PBMC that were included in the broad screen of all 15-mer peptides from the four dominant pools (column
1A), the six volunteers used to confirm recognition of minimal epitopes predicted within positive 15-mers (column 1B) (1A+1B=strategy 1), and the six volunteers
used to confirm recognition of minimal epitopes predicted within 15-mers without the initial screen (strategy 2).
1As classified in reference [42].
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and second immunizations, respectively. These time
points are indicated in Figure 2 and, where appropriate,
in the Tables (see below). Previous studies have con-
firmed that recall T cell responses measured by ELISpot
assay are able to be detected using cryopreserved
PBMCs although such responses are generally of lower
magnitude than fresh cells [14].
Peptides and peptide pools
Sixty-five 15mer peptides overlapping by 11 amino acids
and spanning the full length of CSP (3D7 strain) were syn-
thesized commercially (Mimotopes, VIC, Australia, >80%
purity) and grouped into nine peptide pools containing
three to 12 peptides in each (Figure 1). Four of these pools
(Cp1, Cp2, Cp6, and Cp9) containing 26 peptides (Table 2)
elicited the highest ELISpot responses among the vo-
lunteers who received the Ad-C or Ad-CA vaccines [7]
(Figure 3) and were selected for this study. Minimal
(9-10mer) epitopes were synthesized by Alpha Diagnostics
Intl Inc, San Antonio, TX, USA (>91% purity).
Strategies to identify class I-restricted CSP epitopes
Two strategies were used to identify class I epitopes within
these four immunodominant pools.Strategy 1: Each of the 26 15mers contained within the
four pools was tested individually by ELISpot assay using
PBMC from 10 selected volunteers with sufficient PBMC
available. 15mers positive by this screen were analysed by
NetMHC to identify putative class I-restricted epitopes,
some of which were then synthesized (see below).
Depending upon PBMC availability, the putative epitopes
were tested in HLA-matched volunteers by ELISpot assays
for ability to recall interferon-gamma responses.
Strategy 2: Because there were not sufficient frozen
PBMC available to extend the analysis using the compre-
hensive ELISpot screening with 26 15mers to additional
volunteers, NetMHC predictions were used directly to
identify class I-restricted epitopes within 15mers that
could be matched to six additional volunteers with robust
responses against the parent pool. Some of these minimal
epitopes were also synthesized and tested in ELISpot
assays. As a control, some predicted epitopes were
tested with non-HLA-matched volunteers for whom
PBMC were available.
Ex vivo IFN-γ enzyme-linked immunospot (ELISpot) assays
IFN-γ ELISpot assays were conducted as previously
described [14,41]. Cryopreserved PBMC were suspended
in 100 μL complete medium and stimulated with CSP
Table 2 CSP peptides used in ELISPOT and ICS assays
Pool Amino acids 15mer Amino acids Sequence
Cp1 1 - 39 C1 1-15 MMRKLAILSVSSFLF
C2 5-19 LAILSVSSFLFVEAL
C3 9-23 SVSSFLFVEALFQEY
C4 13-27 FLFVEALFQEYQCYG
C5 17-31 EALFQEYQCYGSSSN
C6 21-35 QEYQCYGSSSNTRVL
C7 25-39 CYGSSSNTRVLNELN
Cp2 29-71 C8 29-43 SSNTRVLNELNYDNA
C9 33-47 RVLNELNYDNAGTNL
C10 37-51 ELNYDNAGTNLYNEL
C11 41-55 DNAGTNLYNELEMNY
C12 45-59 TNLYNELEMNYYGKQ
C13 49-63 NELEMNYYGKQENWY
C14 53-67 MNYYGKQENWYSLKK
C15 57-71 GKQENWYSLKKNSRS
Cp6 309-331 C46 309-323 EEPSDKHIKEYLNKI
C47 313-327 DKHIKEYLNKIQNSL
C48 317-331 KEYLNKIQNSLSTEW
Cp9 357-397 C58 357-371 ELDYANDIEKKICKM
C59 361-375 ANDIEKKICKMEKCS
C60 365-379 EKKICKMEKCSSVFN
C61 369-383 CKMEKCSSVFNVVNS
C62 373-387 KCSSVFNVVNSSIGL
C63 377-391 VFNVVNSSIGLIMVL
C64 381-395 VNSSIGLIMVLSFLF
C65 383-397 SSIGLIMVLSFLFLN
Four CSP peptide pools, Cp1, Cp2, Cp6, and Cp9 were selected as they elicited
the highest responses overall in ELISpot assays with Ad-CA-immunized
volunteers (see reference 7 and Figure 3).
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centration of 10 μg/mL of each peptide tested [41].
Cultures were incubated for 36 hours at 37°C, 5% CO2.
Each PBMC sample was assayed in duplicate, triplicate,
or quadruplicate and the number of IFN-γ-secreting
spot forming cells (sfc) was counted using an automated
ELISpot reader (AID, GmbH, Germany). The positive
control was commercially obtained Class I Peptide Pool
Plus (CEF; Anaspec, USA) that stimulates IFN-γ from
CD8+ T cells [42]. Negative control was media with all
supplements except antigen-specific stimulants. In dupli-
cate assays, both values were used in the analysis. For
triplicate or quadruplicate assays, outliers were rejected
if any single value contributed more than 50% of the
standard deviation of the replicates and if its value was
three-fold greater or three-fold less than the average of
the remaining two (or three) values. The mean number
of sfc obtained in negative control wells was subtractedfrom the value of each test well from the same sample.
Negative counts generated by this background subtrac-
tion were converted to zero. The mean number of spots
of the test sample was then calculated and expressed as
sfc/million (sfc/m). A positive response was defined as a
significant difference (p = <0.05) between the average of
sfc in test wells and negative control wells (Student’s two
tailed t-test), plus at least a doubling of sfc in test wells
relative to negative control wells, plus a difference of at
least 10 sfc between test and negative control wells [7].
Characterization of ELISpot IFN-γ-producing cells by T-cell
subset depletions
PBMC were depleted of T-cell subsets using anti-human
CD4+ or anti-CD8+ coated Dynabeads M-450 (Dynal,
Great Neck, NY, USA) following the manufacturer’s in-
structions as previously described [7]. Mock depletion was
done with Dynabeads coated with sheep anti-mouse IgG.
Flow cytometry confirmed that T-cell subset depletions
were >99% in all experiments. Data are presented as sfc/m
and per cent decrease or increase in activity after depletion.
Intracellular cytokine staining (ICS)
ICS was performed as published previously [14]. Cryo-
preserved PBMC were thawed, washed, and resuspended
at 1×106 cells per mL in complete medium. Peptides were
used at 10 μg/mL and costimulatory antibodies anti-CD28
and anti-CD4 + 9d (BD Bioscience, San Jose, CA, USA)
were used at 1 μg/mL. Stimulants were added to cells and
incubated at 37°C with 5% CO2 for two hours. Cells were
stained with anti-CD3, anti-CD4+, anti-CD8+, anti-IFN-γ,
anti-TNFα, and anti-IL2 and the entire available sample
was acquired on a BD LSRII using FACSDiVa (BD
Bioscience) software. Data were analysed using FlowJo
software (Treestar, Inc). The gating strategy involved pro-
gressively measuring total cells; viable cells; lymphocytes;
T cells; CD4+ or CD8+ populations; and finally a specific
cell type expressing a specific cytokine. Results were trans-
ferred to Prism (GraphPad) for graphing and data were
corrected for media responses. A positive response was
greater than the medium controls + three standard devia-
tions (0.03%).
NetMHC-based epitope predictions
NetMHC [13] was used to predict the MHC class 1 bind-
ing affinities, expressed as the half maximum inhibitory
concentration (IC50) of minimal 8-10mer epitopes within
the 15mers that matched the HLA alleles expressed by the
volunteers used in each assay. Peptides with predicted
IC50 binding affinities less than 500 nM were considered
strong binders, those 500–5,000 nM were considered
weak binders, and those >5,000 nM was considered non-
binders [43].
0200
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Figure 3 ELISpot activity of CSP peptide pools with all volunteers in adenovirus-vectored CSP trials. The ELISpot activities of all subjects
from three adenovirus-vectored CSP trials (see Figure 2) recalled by each CSP peptide pool (Cp1-Cp9) were arranged in ascending order of
activity. The numbers above each peptide pool are the geometric means of activities to that pool. Cp1, Cp2, Cp6 and Cp9 were selected for this
study as the immunodominant pools.
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Volunteers
A total of 17 immunized volunteers were used in all ex-
periments (Table 1): five of six volunteers immunized with
Ad-CA in trial 1 [7]; three of 18 volunteers immunized
with Ad-CA in trial 2 ([9] and nine of 11 volunteers im-
munized with Ad-C in trial 3 (Table 1). These volunteers
expressed a total of 17 different HLA A allele groups
representing all HLA A supertypes [33,44] and 17 HLA B
allele groups representing all HLA B supertypes (Table 1).
ELISpot activity of CSP 15mers with volunteers
immunized with Ad-C or Ad-CA
The hypothesis was that NetMHC would predict minimal
binding epitopes (affinity <5,000 nM) in individual 15mers
positive in ELISpot assay that were restricted by HLA al-
lele groups that matched the HLA expressed by each
volunteer. Each of the 26 15mers within each of the four
dominant pools (Table 2) was used as a stimulant in indi-
vidual ELISpot assays conducted using PBMC from five
volunteers immunized with Ad-CA (v01, v02, v05, v08
and v12) (no CHMI trial) and five volunteers immunized
with Ad-C (v41, v49, v58, v61 and v69). No volunteers
from the Ad-CA with CHMI trial had sufficient PBMC to
be included. All results are shown in Additional file 1 and
the positive results are shown in Table 3.
Fifteen of the 26 tested 15mers were positive by ELISpot
assay (Table 3). Although responses varied, it appeared
that the inclusion of the AMA1 in the Ad-CA vaccine did
not interfere with CSP epitope recognition by PBMC. As
previously seen with NetMHC predictions [33], about 25%
of the 15mers containing putative HLA-matched epitopeswith predicted IC50’s <5,000 nM gave positive responses
(see Additional file 1). No 15mer containing a predicted
epitope was positive with all HLA-matched volunteers,
and no volunteer was always positive with all 15mers
containing predicted HLA-matched epitopes. When the
activity of each positive 15mer was calculated as a per cent
of the parent pool activity, these varied from 25 – 297%,
with percentages < 100% suggesting that the parent pool
may contain other 15mers able to recall responses, and
percentages > 100% suggesting that the various 15mers
in the parent pool may not have been fully processed
and presented.
NetMHC prediction of class I-restricted epitopes within
CSP 15mer peptides
NetMHC predicted 17 HLA-matched minimal epitopes
from the fifteen positive 15mers active in the ELISpot
assay (Table 4), of which 11 were predicted to be strong
binders (IC50 < 500 nM) and five were predicted to be
weak binders (IC50 500-5,000 nM). NetMHC identified
one epitope (E5) where the IC50 (>5,000 nM) was too
low to confirm class I binding (>5,000 nM). The pre-
dicted putative epitopes were numbered E1–E17 in se-
quence from the N-terminal end of CSP. The predicted
epitopes included seven 9mers (E2, E6, E7, E8, E10, E12,
E13) and ten 10mers (E1, E3, E4, E5, E9, E11, E14, E15,
E16, E17). Eleven predicted epitopes were from the N-
terminal region (E1 to E11) and six epitopes were from
the C-terminal region (E12 to E17). Potential putative
epitopes located in regions of the CSP not covered by
the four dominant pools (see Figure 1) were not consid-
ered in this study.
Table 3 ELISpot IFN-γ activity of CSP peptide pools and individual 15-mer peptides within these pools
Pool Vol. Vaccine 15mer peptide AA no. Sequence Pool sfc/m 15mer sfc/m Percent of pool
Cp1 58 Ad-C C3 9-23 SVSSFLFVEALFQEY 116 29 25.0
Cp1 05 Ad-CA C3 SVSSFLFVEALFQEY 142 65 45.8
Cp1 69 Ad-C C3 SVSSFLFVEALFQEY 411 385 93.7
Cp1 12 Ad-CA C4 13-27 FLFVEALFQEYQCYG 64 87 135
Cp1 05 Ad-CA C4 FLFVEALFQEYQCYG 142 44 31.0
Cp1 01 Ad-CA C4 FLFVEALFQEYQCYG 77 48 62.3
Cp1 69 Ad-C C4 FLFVEALFQEYQCYG 411 368 89.5
Cp1 58 Ad-C C5 17-31 EALFQEYQCYGSSSN 116 105 90.5
Cp1 58 Ad-C C6 21-35 QEYQCYGSSSNTRVL 116 83 71.6
Cp2 49 Ad-C C8 29-43 SSNTRVLNELNYDNA 64 41 64.1
Cp2 41 Ad-C C10 37-51 ELNYDNAGTNLYNEL 83 35 42.2
Cp2 49 Ad-C C12 45-59 TNLYNELEMNYYGKQ 64 28 43.8
Cp2 12 Ad-CA C12 TNLYNELEMNYYGKQ 331 411 124
Cp2 01 Ad-CA C12 TNLYNELEMNYYGKQ 119 119 100
Cp2 01 Ad-CA C13 49-63 NELEMNYYGKQENWY 119 116 97.5
Cp2 12 Ad-CA C13 NELEMNYYGKQENWY 331 334 100
Cp6 61 Ad-C C47 313-327 DKHIKEYLNKIQNSL 53 48 90.6
Cp6 41 Ad-C C48 317-331 KEYLNKIQNSLSTEW 95 103 108
Cp6 05 Ad-CA C48 KEYLNKIQNSLSTEW 130 106 81.5
Cp6 58 Ad-C C48 KEYLNKIQNSLSTEW 24 45 187
Cp9 61 Ad-C C60 365-379 EKKICKMEKCSSVFN 128 39 30.5
Cp9 01 Ad-CA C62 373-387 KCSSVFNVVNSSIGL 39 116 297
Cp9 08 Ad-CA C63 377-391 VFNVVNSSIGLIMVL 142 109 76.8
Cp9 08 Ad-CA C64 381-395 VNSSIGLIMVLSFLF 142 91 64.1
Cp9 01 Ad-CA C65 383-397 SSIGLIMVLSFLFLN 39 46 117
Cp9 02 Ad-CA C65 SSIGLIMVLSFLFLN 16 44 275
Cp9 08 Ad-CA C65 SSIGLIMVLSFLFLN 142 62 43.7
All individual 15mer peptides within the CSP peptide pools Cp1, Cp2, Cp6 and Cp9 were tested in ELISpot assay using frozen PBMC collected 28 days after Ad-CA
or 19-23 days after Ad-C immunization. 15 individual 15mer peptides of the 26 15mer peptides elicited positive recall responses from at least one volunteer
immunized with Ad-CA and Ad-C, and each of the ten volunteers responded positively to at least one 15mer.
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Two putative epitopes were predicted to be restricted by
different HLA supertypes (Table 4): E2 by both A*01:01
allele group (A01 supertype) and B*35:01 allele group
(B07 supertype), and E12 by A*02:01 allele group (A02
supertype) and B*08:01 allele group (B08 supertype),
supporting recent meta-analyses that >50% of IEDB-
listed epitopes bind two or more HLA molecules [40].
The remaining putative epitopes were predicted to be re-
stricted by single HLA allele groups: E1, E4, E5, E14 and
E17 by A*02:01 (A02 supertype); E3, E9 and E11 by
A*30:02 (A01 supertype); E15 and E16 by A*68:02 (A02
supertype); E10 and E13 by B*44:02 (B44 supertype); E6
and E8 by B*15:03 (B27 supertype); and E7 by B*35:01
(B07 supertype). Epitopes predicted to bind to supertypes
A03 and B58, which were expressed by some volunteers
(Table 1), were not identified by NetMHC in the 15merspositive in ELISpot from these four selected peptide pools,
although this does not mean definitively that none occur.
ELISpot activity of synthesized minimal epitope peptides
with volunteers immunized with Ad-CA or Ad-C
Six volunteers were selected on the basis of HLA-
matching and availability of PBMC to test in ELISpot as-
says five of the predicted putative epitopes identified
through the comprehensive 15mer screen and NetMHC,
E1, E2, E3, E14 and E18. These were v58, v69, 37 and
v40 from the Ad-C trial and v127 and v156 from the
Ad-CA CHMI trial. The pairing of volunteers and epi-
topes is shown in the top half of Table 5.
A second round of assays was also conducted (strategy
2) to analyse four additional predicted putative epitopes
selected from positive parent 15mers, numbered E19 to
E22. E19 and E20 were predicted to bind to A*24:03 and
Table 4 Predicted CD8+ T cell-restricted epitopes specific for each volunteer within CSP 15mer peptides
Pool 15mer Vol. Predicted epitope AA no. IC50 nM HLA allele group HLA supertype Epitope no.
Cp1 C3 58 SVSSFLFVEALFQEY 13-22 258 A*02:01 A02 E1
05 SVSSFLFVEALFQEY 15-23 50 A*01:01 A01 E2
69 SVSSFLFVEALFQEY 15-23 68 B*35:01 B07 E2
C4 12 FLFVEALFQEYQCYG 14-23 226 A*30:02 A01 E3
01 FLFVEALFQEYQCYG 13-22 258 A*02:01 A02 E1
69 FLFVEALFQEYQCYG 15-23 68 B*35:01 B07 E2
C5 58 EALFQEYQCYGSSSN 18-27 2174 A*02:01 A02 E4
C6 58 QEYQCYGSSSNTRVL 23-32 11714 A*02:01 A02 E5
Cp2 C8 49 SSNTRVLNELNYDNA 32-40 4075 B*15:03 B27 E6
C10 41 ELNYDNAGTNLYNEL 40-48 321 B*35:01 B07 E7
C12 49 TNLYNELEMNYYGKQ 45-53 1087 B*15:03 B27 E8
12 TNLYNELEMNYYGKQ 47-56 25 A*30:02 A01 E9
01 TNLYNELEMNYYGKQ 49-57 468 B*44:02 B44 E10
C13 12 NELEMNYYGKQENWY 54-63 132 A*30:02 A01 E11
Cp6 C47 61 DKHIKEYLNKIQNSL 319-327 27 A*02:01 A02 E12
C48 41 KEYLNKIQNSLSTEW 319-327 27 A*02:01 A02 E12
05 KEYLNKIQNSLSTEW 319-327 83 B*08:01 B08 E12
58 KEYLNKIQNSLSTEW 319-327 27 A*02:01 A02 E12
Cp9 C60 61 EKKICKMEKCSSVFN 371-379 2353 B*44:02 B44 E13
C62 01 KCSSVFNVVNSSIGL 376-385 470 A*02:01 A02 E14
C63 08 VFNVVNSSIGLIMVL 379-388 70 A*68:02 A02 E15
C64 08 VNSSIGLIMVLSFLF 382-391 294 A*68:02 A02 E16
C65 01 SSIGLIMVLSFLFLN 387-396 53 A*02:01 A02 E17*
02 SSIGLIMVLSFLFLN 387-396 53 A*02:01 A02 E17*
08 SSIGLIMVLSFLFLN 387-396 816 A*02:01 A02 E17*
The 15mer peptides that were recognized by the volunteers in the initial screen (Table 2) were analysed by NetMHC to predict affinity HLA binding by minimal
CD8+ T cell epitopes within each 15-mer (underlined and bold). Those minimal epitopes with the strongest binding affinities for the HLA alleles of each volunteer
were selected. Each minimal epitope was specific for a known HLA allele within each supertype. Two listings from Table 4 were not included here because the
same minimal peptide was predicted for the same volunteer for two overlapping 15mers (v01, C12 and C13; v05, C3 and C4). Nine of these epitopes were
synthesized and further screened by ELISpot with HLA-matched volunteers (see Table 5).
*E17, a 10-mer, was predicted to contain a 9mer sequence LIMVLSFLF labelled E18 (see Table 5).
Vol. = volunteer; AA = amino acid; No. = number.
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promiscuously to A*24:02, A*23:01 and A*29:02. Like
E19 and E20, E22 was predicted to bind to A*02:01.
PBMC were available from six HLA-matched volunteers
to test these four additional peptides, including v156
(AdCA, with CHMI), v37 (AdC) and v40 (AdC), all used
to test the first set of epitopes (see above), and three
new volunteers, v125 (AdCA, with CHMI), v63 (AdC)
and v68 (AdC). The pairing of volunteers and these four
additional putative epitopes for the conduct of ELISpot
assays is shown in the bottom half of Table 5.
The positive control for each assay was the parent CSP
peptide pool that contained the 15mer peptide from which
these epitopes were derived (noting that the magnitude of
response recalled by some parent pools was lower than
that recalled by predicted epitope it contained). We alsoconducted six assays where the volunteer and epitope
matched at the supertype but not the allele group level,
and also seven assays constituting HLA mismatches.
Altogether thirty-five assays were conducted using the
nine synthesized epitopes, with the positive assay results
shown in Table 5, ranging from 0 to 331 sfc/106 PBMC
(for all results, see Additional file 2). When the activity
of each positive result was calculated as a per cent of the
parent pool activity, these varied from 35.4 – 674%,
suggesting that the parent pool may contain other epi-
topes that were not tested here (<100%), or that the vari-
ous epitopes in the parent pool may not have been fully
processed and presented (>100%). Interestingly, nearly
all assays (18/20) matching synthesized minimal epitopes
to research subjects by allele group were positive. The
two exceptions were E19 that matched v40 and E22 that
Table 5 ELISpot IFN-γ activity of CSP peptide pools and predicted 8-10mer epitopes within these pools (strategy 1 and
strategy 2)
Pool Vol. Epitope no. Epitope
sequence
AA no. HLA allele group HLA supertype IC50 nM Pool sfc/m Epitope sfc/m Percent of pool
Cp1 581 E1 FLFVEALFQE 13-22 A*02:01 A02 258 ND 49
Cp1 1563 E1 FLFVEALFQE 13-21 A*29:02 A01A24 422 126 105 83.3
E1 FLFVEALFQE 13-20 A*29:02 A01A24 109
Cp1 692 E2 FVEALFQEY 15-23 B*35:01 B07 68 399 268 67.2
Cp1 1273 E2 FVEALFQEY 15-23 A*01:01 A01 63 69 89 129
Cp1 692 E3 LFVEALFQEY 14-23 A*30:02 A01 63 ND 259
Cp1 692 E3 (E2) LFVEALFQEY 15-23 B*35:01 B07 68 399 259 64.9
Cp1 1273 E3 (E2) LFVEALFQEY 15-23 A*01:01 A01 63 69 99 144
Cp9 371 E14 SVFNVVNSSI 376-385 A*68:02 A02 18 79 28 35.4
Cp9 581 E14 SVFNVVNSSI 376-385 A*02:01 A02 470 13 80 615
Cp9 401 E14 SVFNVVNSSI 377-385 A*23:01 A24 1801 434 104, 72 242, 167
Cp9 1563 E18 LIMVLSFLF 387-395 A*29:02 A01A24 190 64 156 244
Cp9 371,2 E18 LIMVLSFLF 387-395 B*15:03 B27 111 794 55, 38 69.6, 48.1
Cp9 401 E18 LIMVLSFLF 387-395 A*23:01 A24 282 434 290, 166 674, 386
Cp1 631 E19 AILSVSSFLF 6-15 A*24:03 A24 1088 ND 41
Cp1 1253 E20 SVSSFLFVEA 9-18 A*02:01 A02 25 27 33 122
Cp1 681 E21 SFLFVEALF 12-20 A*24:02 A24 104 ND 34
Cp1 371,2 E21 SFLFVEALF 12-20 A*23:01 A24 104 364 53, 53 147, 147
Cp1 401 E21 SFLFVEALF 12-20 A*23:01 A24 104 1634 313, 197 192, 121
Cp1 1563 E21 SFLFVEALF 12-20 A*29:02 A01A24 245 120 240 200
Cp9 1253 E22 IMVLSFLFL 388-396 A*02:01 A02 59 58 29 50.0
This table includes all 19 epitope-specific responses that were positive among the 35 that were tested. The presence of two results in the epitope response
column (second from right) indicates that two separate experiments were performed. E18 is a 9mer sequence predicted by NetMHC within E17 (Table 4) and was
synthesized rather than E17 and tested with three volunteers immunized with Ad-CA or Ad-C. Three of the 9mer sequences that are underlined indicate
additional class I-restricted sequences predicted by NetMHC contained within E1 and E14 epitopes respectively. E1 was positive with both the volunteer predicted
to recognize the full sequence and the volunteer predicted to recognize two nested epitopes. E14 was positive for both the two volunteers predicted to
recognize the full sequence and the one volunteer predicted to recognize the nested epitope. A single assay was performed for v69 and E3; however, E3 contains
the E2 sequence that is underlined and has a different predicted restriction than E3, so both are listed. E14 contains a predicted A*23:01-restricted epitope that
is underlined.
1PBMC from 28 days after first Ad-C immunization; 2PBMC from 19 days after second Ad-C immunization; 3PBMC from 28 days after Ad-CA immunization;
4The response to the peptide pool was not done in the second assay.
ND, Not Done.
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where the epitope matched at the supertype but not the
allele group level, and also all seven HLA mismatches,
were negative (Additional file 2).
The findings for each of the nine epitopes were as
follows:
E1 (FLFVEALFQE): This sequence was supported as
an A*02:01-restricted (A02 supertype) epitope as the
synthesized peptide was active with v58 (Table 5). E1
was also positive with v156 who does not express
A*02:01; however, E1 contains the 9mer FLFVEALFQ
and the 8mer FLFVEALF that NetMHC predicted
each bound to A*29:02 that is expressed by v156
(Table 5). Therefore, E1 is A*02:01-restricted and alsocontains two predicted sequences restricted by A*29:02
(both of which are listed in the table).
E2 (FVEALFQEY): This sequence was supported as a
B*35:01-restricted epitope (B07 supertype) as the
synthesized peptide was active with v69 (Table 5). E2
was also predicted by NetMHC to be an A*01:01-
restricted epitope (A01 supertype) using v05; however,
PBMC were not available from v05 to test the
synthesized peptide. E2, however, could be tested with
v127, also A*01:01-restricted, and was active. Therefore
E2 appears restricted by two allele groups, B*35:01 and
A*01:01 that belong to different supertypes, B07 and
A01, respectively.
E3 (LFVEALFQEY): This sequence was initially
identified as A*30:02-restricted, as the parent C4 15mer
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sufficient PBMC from v12, E3 was tested and was
active with v69, concordant with NetMHC-predicted
binding to A*30:02 (A01 supertype). E3 contains the
9mer E2 sequence (FVEALFQEY) that NetMHC
predicted binds to B*35:01 that is also expressed by v69
(see E2 above). Both potential HLA associations
(A*30:02, B*35:01) for v69’s positive result (259 sfc/m)
are listed in Table 5. E3 was also positive with v127,
concordant with the NetMHC prediction that the E2
sequence within E3 bound to A*01:01 (see E2 above).
Therefore, activities of E3 with v127 and v69 are
similar to those of E2, with the same allele group
restrictions, B*35:01 and A*01:01 (B07 and A01
supertypes, respectively).
E14 (SVFNVVNSSI): This sequence was initially
identified as A*02:01-restricted as the parent 15mer,
C62, was positive with v01 (Table 4). Since there were
not sufficient PBMC from v01, it was tested with v58
who shared the same HLA allele, A*02:01 (A02
supertype). E14 was also positive with v37 and
NetMHC predicted binding to A*68:02 that like
A*02:01 is part of the A02 supertype. E14 was also
positive with v40 and NetMHC predicted a 9mer
sequence VFNVVNSSI contained within E14 that is
restricted by A*23:01 (A24 supertype). Therefore we
conclude that E14 is restricted by A*02:01 and A*68:02
(both A02 supertype) and contains a sequence that is
predicted to be restricted by A*23:01 (A24 supertype).
E18 (LIMVLSFLF): This was positive with v156 and
NetMHC predicted this sequence binds to A*29:02
(A01A24 supertype) that is expressed by v156. E18 was
also positive with v37 and NetMHC predicted this
sequence also binds to B*15:03 (B27 supertype). Finally,
E18 was positive with v40, and NetMHC predicted
binding to A*23:01 (A24 supertype). Therefore, E18
ELISpot activity was restricted by three allele groups,
A*29:02, B*15:03 and A*23:01 that are members of
three HLA supertypes, A01A24, B27 and A24,
respectively. E17, which was not synthesized since
several other A*02:01-restricted putative epitopes were
tested (E1, E14, E20 and E22), has not yet been
confirmed as A*02:01-restricted in ELISpot assays.
E19 (AILSVSSFLF): This sequence was predicted as
an A*23:01 (A24 supertype)-restricted epitope using
v40. Since there were not sufficient PBMC from v40,
E19 was tested and was positive with v63 who
expresses A*24:03 that is also a member of the A24
supertype. NetMHC predicted that this 10mer was
A*24:03-restricted (A24 supertype) with a low
binding affinity (IC50 1088 nM). Therefore, it was
concluded that E18 may be restricted by A*23:01
and A*24:03, both of which are members of the A24
supertype.E20 (SVSSFLFVEA): This sequence was predicted to
be A*68:02-restricted (A02 supertype) using v52. Since
PBMC were not available from this volunteer, E20 was
tested and was active with v125 who does not express
A*68:02. However, NetMHC predicted that a 8mer
contained within E20 (SVSSFLFV) is restricted by
A*02:01 that is expressed by v125 and is also A02
supertype. Therefore E20 may be A*68:02-restricted,
but ELISpot assay and NetMHC suggested that it
contains a 8mer that is A*02:01-restricted (A02
supertype).
E21 (SFLFVEALF): This sequence was positive with
v37; NetMHC predicted binding to A*23:01 (A24
supertype) that is expressed by v37. E21 was also
positive with v40 who also expressed the A*23:01 allele
group. In addition, E21 was positive with v156 and
NetMHC predicted binding to A*29:02 that is expressed
by v156. E21 was also moderately positive with v68;
NetMHC predicted binding to A*24:02 expressed by v68
that like A*23:01 is a member of the A24 supertype.
Therefore, E21 appears to be restricted by A*23:01 and
A*24:02 (both A24) and A*29:02 (A01A24).
E22 (IMVLSFLFL): This sequence gave a modest
response against v125 and NetMHC predicted that E22
is A*02:01-restricted as A*02:01 is expressed by v125.
In addition, E22 partially overlaps a 10mer
LIMVLSFLFL that is also predicted to be A*02:01-
restricted consistent with v125 expressing the A02
supertype.
Confirmation of class 1-restriction of epitopes using
ELISpot depletion and ICS assays
PBMC from HLA-matched volunteers were available to
conduct confirmatory assays for six of the nine predicted
minimal epitopes tested: E1, E2, E14, E18, E20 and E21.
After CD8+ T cell depletion, ELISpot activities against
E1, E2, E18, E21 were reduced by 73%-96% (Table 6)
whereas depletion of CD4+ T cells did not affect activity
(reduction <18%). For E14, depletion of CD8+ and CD4+
T cells reduced activity approximately equally (56% and
50%, respectively). However, CD8+ T cell depletion did
not affect activity of E20 whereas CD4+ T cell depletion
reduced activity by 78%, suggesting that the response was
not CD8+ T cell-dependent. When these epitopes were
tested by ICS, results were consistent with the ELISpot
depletion studies. CD8+ T cell interferon-gamma re-
sponses were recalled by E1, E2, E14, E18 and E21 at fre-
quencies ranged from 0.12% (E14) to 0.54% (E18) of gated
CD8+ T cells, similar to the parent pools, except for E20,
where the CD8+ T cell frequency was only 0.06%. CD4+ T
cell responses were negligible (≤0.04%). Therefore, five
epitopes (E1, E2, E14, E18 and E21) of these six pre-
dicted epitopes were confirmed as minimal CD8+ T
cell-dependent epitopes, while E20 was not.
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epitopes identified in this study
The confirmed minimal CSP epitopes are summarized
in Table 7. Seventeen 9-10mer epitopes (E1–E17) were
initially identified using NetMHC predictions of binding
to the HLA A and B alleles expressed by a panel of Ad-
CA and Ad-C-immunized volunteers (Tables 3 and 4).
Five of these epitopes were synthesized (E1, E2, E3, E14
and E18) and tested in ELISpot assays. Four of these five
epitopes were tested in ELISpot depletion and ICS assays
(E1, E2, E14 and E18). Derived from strategy 2, four
additional epitopes were synthesized (E19, E20, E21 and
E22) and likewise demonstrated activity in ELISpot as-
says, and two of these were tested in ELISpot depletion
and ICS assays (E20, E21). Overall, the restricted avail-
ability of PBMC from immunized volunteers allowed
only five of these epitopes (E1, E2, E14, E18, and E21) to
be confirmed as recalling CD8+ T cell responses. One
additional epitope E20 was tested but could not be con-
firmed. All 9 of the putative epitopes that were synthe-
sized and studied in ELISpot assays are conserved.
HLA allele promiscuity of identified epitopes using
ELISpot assays
This study could not be extended to many subjects due
to limited PBMC samples, but nevertheless supported
previous findings that some class I epitopes are suffi-
ciently degenerate to bind to more than one allele group
or supertype [24]. As shown in Table 7, E2 was re-
stricted by A*01:01 (A01 supertype) and B*35:01 (B07
supertype), and E18 was restricted by A*23:01 (A24Table 6 ELISpot IFN-γ activity of CSP predicted epitopes after
CD8+ and CD4+ T cell IFN-γ activity
Vol. Pool Epitope no. Sequence HLA allele
group
Control
sfc/m
V401 Cp1 97
E21 SFLFVEALF A*23:01 254
E14 SVFNVVNSSI A*23:01 86
E18 LIMVLSFLF A*23:01 236
V692 Cp1 445
E2 FVEALFQEY B*35:01 380
V1253 E20 SVSSFLFVEA A*02:01 79
V1563 Cp1 133
E21 SFLFVEALF A*29:02 213
E1 FLFVEALFQE A*29:02 245
Cp9 E18 LIMVLSFLF A*29:02 307
1PBMC from one month after the first Ad-C immunization; 2PBMC from 19 days afte
following Ad-CA immunization.
*The percent change in ELISpot activity is shown after depletion of CD4+ or CD8+ T
**The percent of CD8+ or CD4+ gated T cells expressing IFN-γ.
depl. = depletion.
sfc/m = spot forming cells/million.
v125 did not have sufficient PBMC to test Cp1.supertype), A*29:02 (A01A24 supertype) and B*1503
(B27 supertype). E14 was restricted by two allele groups
of the A02 supertype (A*02:01 and A*68:02), and E21
was restricted by two allele groups of the A24 supertype
(A*23:01 and A*24:02) and one allele group of the A01A24
supertype (A*29:02). This promiscuity of restriction is likely
underestimated due to the limited availability of PBMC
from the 17 volunteers used in this study. When
NetMHC was used to predict all restrictions of epitopes
within Cp1, Cp2, Cp6 and Cp9, many more potential
restrictions were identified that could not be evaluated
or verified in this study.
Epitope localization
Among the 17 predicted putative epitopes, 11 were loca-
lized in the N-terminal region, and six were localized to
the C-terminal region. Among the nine epitopes that were
synthesized and tested in ELISpot assays, six were loca-
lized to the N-terminal region (E1, E2, E3, E19, E20, and
E21) and three epitopes were localized to the C-terminal
regions (E14, E18 and E22). Recently part of the strain
3D7 CSP C-terminal region (aa 310–375) has been crys-
tallized revealing a unique αTSR domain related to other
TSR domains that contains a hydrophobic pocket contigu-
ous with the hydrophobic core [45]. Only one of the C-
terminal epitopes described here completely lies within
the crystallized sequence, E12 (Table 4), which is localized
on an outer α1 helix that forms the edge of the hydropho-
bic pocket, and partially overlaps the Th2R epitope. How-
ever, E12 was not tested by itself although the two 15mers
containing E12, C47 and C48, were tested in these assays.depletion of CD4+ and CD8+ T cells compared with ICS
depl. CD8+ depl. sfc/m
(%)*
CD4+ depl. sfc/m
(%)*
CD8+
%**
CD4+
%**
5 (-95%) 82 (-15%) 0.44 0.02
15 (-94%) 226 (-11%) 0.37 0.04
38 (-56%) 43 (-50%) 0.12 0.01
23 (-90%) 210 (-11%) 0.54 0.02
6 (-98%) 397 (-11%) 0.53 0.01
17 (-96%) 356 (-6%) 0.48 0.00
72 (-9%) 17 (-78%) 0.06 0.02
0 (-100%) 135 (+2%) 0.33 0.01
29 (-86%) 273 (+28%) 0.25 0.01
91 (-73%) 215 (-12%) 0.34 0.03
85 (-82%) 264 (-18%) 0.26 0.01
r the second Ad-C immunization; 3PBMC from 28 days after challenge
cells.
Table 7 Summary of predicted and confirmed minimal CSP identified in this study epitopes
15mer
peptide
Epitope
number
Sequence AA no. 15mer ELISpot
activity
Epitope ELISpot
activity
Depl. /ICS HLA allele
group
HLA
supertype
Cp1-C3 E1 FLFVEALFQE 13-22 + + + A*02:01 A02
FLFVEALFQE 13-21 A*29:02 A01A24
FLFVEALFQE 13-20 A*29:02 A01A24
E2 FVEALFQEY 15-23 + + ND A*01:01 A01
FVEALFQEY 15-23 + + + B*35:01 B07
Cp1-C4 E3 LFVEALFQEY 14-23 + + ND A*30:02 A01
Cp9-C62 E14 SVFNVVNSSI 376-385 + + ND A*02:01 A02
+ A*68:02 A02
SVFNVVNSSI 377-385 + + A*23:01 A24
Cp9-C65 E18 LIMVLSFLF 387-395 + + A*23:01 A24
+ + A*29:02 A01A24
+ B*15:03 B27
ND
Cp1-C1 E19 AILSVSSFLF 6-15 + ND A*24:03 A24
A*23:01 A24
Cp1-C2 E20 SVSSFLFVEA 9-18 + (+) A*02:01 A02
Cp1-C3 E21 SFLFVEALF 12-20 + + A*23:01 A24
+ + A*29:02 A01A24
+ ND A*24:02 A24
Cp9-C65 E22 IMVLSFLFL 388-396 + ND A*02:01 A02
+ = Positive activity of the 15mer and predicted epitope in ELISpot assay, or recall of CD8+ T cells in ELISpot depletion (Depl.) assay or intracellular staining/flow
cytometry (ICS) assay. (+) = Result not conclusive.
Underlined sequences indicate NetMHC-predicted putative class I-restricted epitopes within E1, E14 and E20.
The five epitopes with + in the Depl./ICS column are confirmed as CD8+ dependent.
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confirmed E14, E18 and E22 localize to a short stretch (aa
376–396) that also contains the GPI anchor leading to the
CSP C-terminus [45].
Summary of functional epitopes within Plasmodium
falciparum CSP
The summary of these newly identified epitopes, as well as
those previously identified, is shown in Figure 1. Cp1, Cp2,
Cp6 and Cp9 contain seven, eight, three and eight 15mer
peptides, respectively, that overlap previously described
A*02:01-restricted epitopes as shown in Figure 1. C1 over-
laps D4 and C2 overlaps D3 but neither 15mer was positive
by our criteria with volunteers expressing A*02:01 (see
Additional file 1). C65 overlaps D2, and this 15mer was
positive with v01 and v02 which do express A*02:01, and
we identified an A*02:01-restricted epitope, E17, that over-
laps D2, but E17 was not synthesized and tested in ELISpot
assays. C47 and C48 overlap D5 that is A*02:01-restricted
and both were positive in ELISpot assays with volunteers
expressing A*02:01 (v61, v41, and v58, Table 4) and the
NetMHC-predicted epitope, E12, is the same as D5. How-
ever, NetMHC also predicted E12/D5 to be B*08:01-restricted but E12 was not tested in the ELISpot assay with
volunteers expressing A*02:01 or B*08:01.
Discussion
Adenovirus-vectored vaccines (Ad-C and Ad-CA) are
being developed to induce the CD8+ T cell responses
thought to be required for protection against liver stage
malaria [7]. The aim of this study was to better understand
the cell-mediated immune responses targeting CSP elic-
ited by these vaccines by mapping MHC class I restricted
epitopes. The long-term goal was to aid the development
of a broadly protective malaria vaccine for genetically
diverse populations. To date, only a few class I-restricted
epitopes have been described for CSP [24,27,46,47] and
these earlier observations have now been extended by
identifying additional class I-restricted epitopes.
As a first step, the computer algorithm NetMHC [48]
was used to predict 11 putative minimal class 1-
restricted epitopes within 15mer CSP peptides that were
active in ELISpot assays conducted using PBMC from
research volunteers immunized with the Ad-C- and Ad-
CA-malaria vaccines. Although most HLA-restricted
peptides have binding affinities of less than 50 nM,
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we focused on putative epitopes with predicted binding
affinities of less than 500 nM. One of these epitopes,
E12, has been previously described as D5 (Figure 1)
specific for HLA A*02:02, although it was also predicted
to bind to HLA B*08:01 in the studies reported here.
While peptide binding to class I MHC molecules is
required for T cell recognition, many peptides that bind
with high affinity are not recognized by T cells [33].
Therefore, it was necessary to demonstrate that these
predicted epitopes were recognized by CD8+ T cells
from Ad-C and Ad-CA-immunized volunteers. Five of
the predicted epitopes were synthesized and tested with
PBMCs from volunteers from the same clinical trials,
and all were active as predicted with at least one HLA-
matched volunteer. As a second approach, the direct
prediction of putative class 1-restricted epitopes was
pursued within parent pools that gave robust responses
with selected volunteers without first screening individ-
ual 15mers in the ELISpot assay. Four of these epitopes
were synthesized and tested, and again, all were active
when tested with PBMC from HLA-matched volunteers.
Thus NetMHC proved to be a valuable tool to predict
epitopes within the parent pool to which the volunteers
strongly responded with or without a preliminary screen
of individual 15mers. Altogether, 18/20 matched epi-
tope/volunteer pairings used to test the nine synthesized
9-10mers were positive on ELISpot assay. None of these
nine putative epitopes has been previously described and
all are therefore novel [49]. Having to rely on PBMC that
were available meant that the evaluation could not be
comprehensive, and indeed many more epitopes were
predicted than could be tested.
It was possible to further test six of the nine synthesized
epitopes by conducting additional ELISpot assays follow-
ing CD4+ or CD8+ T cell depletion, and by conducting
flow cytometry to phenotype the lymphocytes. Of the six
epitopes tested, five demonstrated CD8+ T cell-dependent
recall responses. These five also demonstrated a predom-
inant CD8+ T cell response on flow cytometry. The fact
that most class I-binding peptides are eight to 10 amino
acids, while class II peptides range from 12 to 24 residues
[24,50], supports the likelihood that the novel epitopes are
class I-restricted.
Although testing of previously defined epitopes was not
done, some 15mers tested contained previously identified
epitopes. As one example, ELISpot activity was not dem-
onstrated using two 15mers that overlap known A*02:01-
restricted epitopes: C1 which overlaps D4, and C2 which
overlaps D3. The reason for the lack of recall responses to
these 15mers is unclear but probably it was not due to a
false prediction by NetMHC, since comparative studies
using NetMHC and other predictive algorithms found
NetMHC to be the best performer across all HLAmolecules, and particularly for predicting epitopes binding
to A*02:01 molecules [51]. D4 and D3 were originally
identified using PBMC from individuals living in a
malaria-endemic area and therefore are recognized by nat-
urally acquired immune CD8+ T cells, whereas in this
study the Ad-C or Ad-CA vaccines may not induce the
same responses as natural transmission. The lack of in-
duced response might also have related to the fact that D4
and D3 lie within the signal sequence of CSP (aa 1–18,
Figure 1) that may be cleaved during adenovirus expres-
sion of CSP in human cells and not efficiently processed
and presented. A second example is provided by the C65
15mer that contains D2, which was also identified in indi-
viduals from malaria-endemic areas. In this case, unlike
C1 and C2, C65 was positive in the ELISpot assay. This
could reflect recognition of D2, or could also reflect other
HLA-matched epitopes that were present in C65. Since
D2, D3 and D4 were not tested as minimal epitopes, it
was not possible to confirm whether a response mimick-
ing naturally-acquired immunity, which responds to these
epitopes, was induced by Ad-C or Ad-CA immunization.
Future studies are planned to determine whether the
novel epitopes identified in this study are also recognized
by naturally-exposed individuals.
Of interest is that the RTS,S vaccine contains six pre-
viously described class I-restricted epitopes (D7, D1, D5,
D6, D9 and D2) as well as three novel class I-restricted
epitopes described here (E14, E18 and E22), yet, except
for one observation [2], CD8+ T cell responses have not
been described in RTS,S clinical trials [1]. The reasons
for the lack of RTS,S-induced CD8+ T cell responses re-
main unclear but may be related to antigen presentation
and processing of a protein-based vaccine as opposed to
gene-based vaccines or may reflect the type of stimu-
lants, such as the long synthetic peptides or recombinant
proteins used to recall T-cell responses in some of the
RTS,S immunological studies.
Earlier analyses of P. falciparum epitopes including
CSP have suggested a high degree of degeneracy such
that minimal 8-10mer peptides bind to more than one
HLA allele within different supertypes [24]. This is
consistent with findings that many different HLA alleles
overlap in their peptide-binding properties [24,31-
33,52-54]. Further examples were found in our study
when NetMHC predictions of the HLA-restrictions of
peptides spanning the full length of CSP were analysed
(data not shown) suggesting that this HLA supertype
promiscuity may be extensive. Promiscuous class I-
restricted epitopes that recognize different HLA
supertypes have been reported for viral diseases
suggesting that many epitopes can be presented on dif-
ferent HLA alleles [38,39], with certain allele pairs
frequently sharing epitopes [39]. In this study, the small
number of epitopes formally tested precluded a
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degeneracy in the peptides that were studied provides
encouraging evidence that a CSP adenovirus-vectored
vaccine may be immunogenic in genetically diverse
populations.
Broad applicability of the vaccine is supported by the
lack of sequence variation observed in malaria-endemic
areas for most of these epitopes, including all 9 that were
synthesized [16,55,56]. Amino acid polymorphism may be
associated with surface accessibility or immune pressure
[56,57]. A large study involving isolates from Kenya, India,
Cameroon and Venezuela identified only five polymorphic
residues in the N-terminus of CSP [16,55]; one of these, a
threonine, occurs in the E6 epitope described here. How-
ever, an analysis of the sequence of 3D7 CSP compared
with nine other strains indicated that aa 1–63 containing
E1-E11 as well as aa 371–396 containing E13-E22 are con-
served, with only aa 324, 325 and 327, located within E12,
showing variability. More frequent polymorphisms are
found within the Th2R and Th3R epitopes, which do not
overlap the epitopes described in this study [16,55,56].
More investigations are needed to determine the extent of
polymorphism in class I-restricted epitopes, for example
by comparison of sequenced genomes of strain 3D7 with
endemic isolates using new technologies [58] that focus
on CSP T cell epitopes [59].
Recent studies have suggested that the N-terminal
region of CSP folds over and protects the C-terminal
region, exposing the N-terminal and repeat regions [4].
CSP peptide pools containing peptides spanning the N-
terminus recalled strong CD8+ T cell responses in Ad-C
and Ad-CA-immunized volunteers. However, CSP pep-
tide pools containing peptides spanning the C-terminal
region recalled CD8+ T cell responses of similar magni-
tude, indicating that immune recognition is not related
to localization within the protein sequence as found for
other pathogens such as hepatitis C, HIV and influenza
viruses [60]. Part of the N-terminal region containing
E1, E2, E3, E19, E20 and E21 is proteolytically cleaved
during sporozoite invasion, while truncated CSP
containing E14, E18 and E22 is carried into the hep-
atocyte [4,45,61], suggesting that N- and C-terminal
epitopes may be processed and presented to the im-
mune system by different mechanisms. The epitopes
identified here are contained within four immuno-
dominant CSP peptide pools, and it is possible that
immunodominance is influenced by differences in
antigen processing [62].Conclusions
This study identified nine putative, conserved minimal
epitopes of which five were confirmed as recalling CD8+
T cell responses. These are restricted by four HLA-Aand two HLA-B supertypes that together are expressed
by 99.5% of Caucasians and 98.1% African Americans
[31]. Several of the CSP class I epitopes were found to
be degenerate, recognized by multiple HLA alleles, con-
sistent with prior reports [24]. Therefore it is likely that
these adenovectored CSP vaccines will elicit CD8+ T cell
responses in most Caucasian and African populations.
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